One trial, read closely
Semaglutide Heart Failure: What the Trials Show
The STEP-HFpEF result, set in the wider cardiovascular-outcome record that surrounds it.
The short version
The semaglutide heart failure evidence centers on one specific kind of heart failure: HFpEF, which stands for heart failure with preserved ejection fraction — a form where the heart pumps with normal force but is too stiff to fill well, and the lungs and legs back up with fluid. It is closely tied to obesity. In a trial built around obesity-related HFpEF, called STEP-HFpEF, once-weekly semaglutide 2.4 mg improved heart-failure symptoms and the physical limits people felt, and produced more weight loss than a placebo. That is a meaningful, measured result in a hard-to-treat condition. It sits inside a larger story: in people who already have heart disease, semaglutide also lowered the rate of serious heart events. This page reads the heart-failure trial first, then sets it beside that wider record. Nothing here is a dose or medical advice.
STEP-HFpEF: the result
STEP-HFpEF studied people who had heart failure with preserved ejection fraction together with obesity. Once-weekly semaglutide 2.4 mg improved heart-failure-related symptoms and physical limitations — captured on a standard symptom-and-function score — and produced greater weight loss than placebo [9]. Two things make the result notable. First, HFpEF has historically been resistant to drug therapy, so a symptom-and-function improvement is not a small thing. Second, the trial targeted the obesity-linked form of the condition specifically, which matches the population semaglutide most affects on the scale. The trial measured symptoms and physical capacity rather than a hard mortality endpoint, so it is read here for what it showed: better symptoms and function, plus weight loss, in obesity-related HFpEF.
The cardiovascular record around it
The heart-failure finding does not stand alone; it sits in a deep cardiovascular-outcome record. In SELECT, in 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, once-weekly semaglutide 2.4 mg cut the combined rate of cardiovascular death, nonfatal heart attack and nonfatal stroke by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) [3]. In SUSTAIN-6, in type 2 diabetes at high cardiovascular risk, the same composite fell by about a quarter (HR 0.74; 95% CI 0.58-0.95), though diabetic-retinopathy complications were more frequent in that population (HR 1.76; 95% CI 1.11-2.78) [2]. The oral form was noninferior to placebo for major cardiovascular events in PIONEER 6, with a numerically lower event rate [8]. Read together, the heart-failure symptom benefit and the broader event reductions are the reason the cardiovascular lens leads this site.
What the heart data does and doesn't say
Precision matters here. The STEP-HFpEF trial showed symptom and physical-function improvement plus weight loss in obesity-related HFpEF [9] — it is not evidence about every type of heart failure, and it is not a claim that semaglutide treats heart failure broadly. The SELECT and SUSTAIN-6 trials showed reductions in the bundled MACE endpoint in defined high-risk populations [3][2] — they are not a promise of benefit for an individual. And the retinopathy signal in SUSTAIN-6 is a real caution in people with pre-existing diabetic eye disease undergoing rapid blood-sugar correction [2][5], detailed on the effects page. This notebook records what each trial measured, in the population it studied, and leaves the clinical decision where it belongs — with a prescriber.